IncyteMEX:INCY 84 Market Cap is MXN398,107 Mil as of Jun. 29, 2026. GuruFocus rates MEX:INCY with a GF Score™ of 84/100 and a GF Value™ of MXN1,464.02 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,428 Biotechnology companies, Incyte ranks better than 98.95% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Incyte's share price for the quarter that ended in Mar. 2026 was MXN1743.68. Incyte's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 200 Mil. Therefore, Incyte's market cap for the quarter that ended in Mar. 2026 was MXN348,645 Mil.
Incyte's quarterly market cap
increased
from Sep. 2025 (MXN317,556 Mil) to Dec. 2025 (MXN348,186 Mil) and
increased
from Dec. 2025 (MXN348,186 Mil) to Mar. 2026 (MXN348,645 Mil).
Incyte's annual market cap
declined
from Dec. 2023 (MXN365,364 Mil) to Dec. 2024 (MXN287,443 Mil) but then
increased
from Dec. 2024 (MXN287,443 Mil) to Dec. 2025 (MXN348,186 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Incyte's Enterprise Value for Today is MXN328,448 Mil.
Incyte (MEX:INCY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Incyte Market Cap Related Terms
Incyte Market Cap Historical Data
* Premium members only.
The historical data trend for Incyte's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:INCY vs INSM, BNTX, ROIV: Market Cap Comparison
For the Biotechnology subindustry, Incyte's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incyte Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Incyte's Market Cap distribution charts can be found below:
* The bar in red indicates where Incyte's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Incyte's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incyte (MEX:INCY) has a Market Cap of MXN398,107 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Incyte and its competitors. According to the industry distribution chart, Incyte ranks #15 out of 1428 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Incyte's Market Cap too high?
Incyte's current Market Cap is MXN398,107 Mil. Based on the distribution chart, Incyte ranks #15 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Incyte has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Market Cap compare to INSM and BNTX?
According to the Biotechnology industry distribution chart, Incyte ranks #15 out of 1428 companies for Market Cap. This places Incyte in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Incyte and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incyte's current Market Cap is MXN398,107 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,464.02, compared to a current price of MXN1,676.03 — trading 14.5% above its estimated fair value. The current Market Cap is MXN398,107 Mil. Incyte's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Market Cap is MXN398,107 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Incyte (MEX:INCY) Overvalued in 2026?
Based on GuruFocus' analysis, Incyte stock appears to be overvalued.
The current stock price of MXN1,676.03 is trading 14.5% above its estimated GF Value™ of MXN1,464.02.
GuruFocus considers Incyte to be Modestly Overvalued.
Key valuation signals for MEX:INCY:
Market Cap: MXN398,107 Mil
GF Value™: MXN1,464.02 vs. price of MXN1,676.03 (14.5% above fair value)
No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
84GF Score
Get the complete analysis for MEX:INCY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INCY has been successfully added to your 
